A retrospective study26 reported that an EGFR-TKI combined with bevacizumab achieved a median OS of 13.5 months and a median PFS of 4.1 months in 24 EGFR-mutant NSCLC patients who had acquired resistance to EGFR-TKIs, especially in T790M-negative patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.